This can lead to more complications, such as: Acute pancreatitis can have a mortality rate of up to 2%, but this can be much higher for severe cases. With the SIRS, the mortality rate rises to 25%.

CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

dose-ranging study designed to determine the dose-response and efficacy of Auxora in patients with acute pancreatitis and accompanying systemic inflammatory response syndrome (SIRS). Patients in ...

is a rare but distinct subtype of chronic pancreatitis. AIP is best described as the pancreatic manifestation of a systemic fibroinflammatory conditions. The systemic disease of which AIP is a ...

Like SIRS, COVID-19 pneumonia is characterized ... and the reduction of complications of AP including necrotizing pancreatitis. Looking to the future, in the first half of 2022, CalciMedica ...

Like SIRS, COVID-19 pneumonia is characterized ... and the reduction of complications of AP including necrotizing pancreatitis. Looking to the future, in the first half of 2022, CalciMedica ...